To Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine Compared to Prevenar™, Co-administered With DTPw-HBV/Hib & OPV or IPV Vaccines as a 3-dose Primary Immunization Course During the First 6 Months of Age

Trial Profile

To Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine Compared to Prevenar™, Co-administered With DTPw-HBV/Hib & OPV or IPV Vaccines as a 3-dose Primary Immunization Course During the First 6 Months of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Apr 2009 Results published in The Pediatric Infectious Disease Journal.
    • 16 Oct 2008 Study start date changed from March 2006 to August March 2006, as reported by ClinicalTrials.gov.
    • 09 Oct 2008 Study start date changed from August 2006 to March 2006, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top